A Study to Evaluate the Safety and Efficacy of Intranasal Esketamine in Treatment-resistant Depression
NCT01998958 · SYNAPSE · Janssen Research & Development, LLC
What it is testing
Summary
Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.
What counts as success
Primary outcome measures
Panel A and B: Change From Baseline (Day 1) in Montgomery Asberg Depression Rating Scale (MADRS) Total Score at Day 8- Analysis of Covariance (ANCOVA) Analysis
Measured over Baseline (Day 1) and Endpoint (Day 8) of Period 1
Panel A and B: Change From Baseline (Day 8) in Montgomery Asberg Depression Rating Scale Total Score at Day 15- ANCOVA Analysis
Measured over Baseline (Day 8) and Endpoint (Day 15) of Period 2
A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.
Who can take part
Eligibility, as published
Where
25 study sites
| Facility | City | Region | Country |
|---|---|---|---|
| — | Birmingham | Alabama | United States |
| — | Garden Grove | California | United States |
| — | Hartford | Connecticut | United States |
| — | Jacksonville | Florida | United States |
| — | Tampa | Florida | United States |
| — | Atlanta | Georgia | United States |
| — | Chicago | Illinois | United States |
| — | Hoffman Estates | Illinois | United States |
| — | Rockville | Maryland | United States |
| — | Cedarhurst | New York | United States |
| — | New York | New York | United States |
| — | Allentown | Pennsylvania | United States |
| — | Philadelphia | Pennsylvania | United States |
| — | Memphis | Tennessee | United States |
| — | Lede | — | Belgium |
| — | Akita | — | Japan |
| — | Hiroshima | — | Japan |
| — | Ichikawa | — | Japan |
| — | Kanzaki | — | Japan |
| — | Kashihara | — | Japan |
| — | Kitakyushu | — | Japan |
| — | Kodaira | — | Japan |
| — | Kumamoto | — | Japan |
| — | Nagano | — | Japan |
| — | Shibukawa | — | Japan |
On the registry
Contact the trial directly
This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.
Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.
NCT01998958 on ClinicalTrials.gov →
Last updated in the registry 2025-04-29. Registry records change; this page reflects the data build of 2026-08-25.
Related